close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 5 Next >
News headline image
Press Release: Sanofi in discussions to sell a controlling stake in Opella
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Availability of the Q3 2024 Aide mémoire
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Online availability of Sanofi’s half-year financial report for 2024
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
From Sanofi - Aventis Groupe
Via GlobeNewswire
News headline image
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today